VCU

Culpeper, VA, United States
Culpeper, VA, United States

Time filter

Source Type

News Article | May 10, 2017
Site: www.prnewswire.com

All the promotions are effective May 10, 2017. Blue, Leopold and Reid will continue to report to Thomas F. Farrell, II, Dominion Energy chairman, president and chief executive officer. Murray will continue to report to Mark O. Webb, senior vice president–Corporate Affairs and chief legal officer. "Dominion Energy is fortunate to have an exceptional leadership team that is guiding the company through the largest growth initiative and best operating and environmental performance in its history," Farrell said. "The promotions recognize the talents and dedication of these individuals, and valuable contributions they are making to the benefit of our shareholders, customers, communities and employees." Blue joined Dominion Energy in 2005 as managing director–State Affairs & Corporate Public Policy, and later was promoted to vice president–State & Federal Affairs. He served in a number of executive positions in Dominion Virginia Power, Corporate Affairs and Law, before assuming his current post in January 2017. Blue served as counselor and director of policy for former Virginia Gov. Mark R. Warner from 2002 to 2005, and was a partner with the law firm of Hogan & Hartson prior to that. He is a member of the boards of directors of the Virginia Foundation for the Humanities, the Virginia Healthcare Foundation, Communities In Schools of Virginia, and Sports Backers. Blue has a bachelor's degree from the University of Virginia and a law degree from Yale Law School. He also has an MBA from the University of Virginia's Darden School of Business. Leopold joined Dominion Energy in 1995 as assistant project manager. She was promoted to vice president–Business Planning & Market Analysis in 2004. Her recent posts include senior vice president–Business Development & Generation Construction, senior vice president–Dominion Transmission, and President–Dominion Energy when that was the prior name of the company's natural gas business unit. Leopold is a member of the board of trustees of Virginia Union University, chair of the board of directors of the Interstate Natural Gas Association of America, and a member of the board and executive committee of the American Gas Association. She has a bachelor's degree in mechanical and electrical engineering from the University of Sussex in the United Kingdom, a master's degree in electrical engineering from George Washington University, and an MBA from Virginia Commonwealth University. Reid joined Dominion Energy as assistant general counsel in January 1996 and was named vice president‒Governance and corporate secretary in October 2007. She became vice president, general counsel, chief compliance officer and corporate secretary in January 2011 and served in a number of other executive positions before assuming her current post in January 2014. Before joining Dominion Energy, Reid was an associate at McGuireWoods and Hunton & Williams. Reid is a member of the boards of directors of the Virginia Repertory Theatre, Energy Mutual Insurance, and the Richmond World Affairs Council, and serves on the board of trustees of Collegiate School.  A graduate of James Madison University, she received her law degree from the University of Richmond's T.C. Williams School of Law. Murray joined Dominion Energy in 2007 as managing director–Corporate Public Policy, after serving as legislative director for former Virginia Gov. Tim Kaine.  Before that, he was deputy director of policy for former Virginia Gov. Mark Warner and served as a vice president with the Virginia Hospital and Healthcare Association. Murray is a member of the boards of the State Council of Higher Education, the Virginia Chamber of Commerce, the Virginia Oral Health Coalition, the Richmond Behavioral Health Authority Foundation, and the Virginia Center for Health Innovation. He also is an adjunct professor at the VCU School of Medicine. Murray has a bachelor's degree from the University of Virginia and a master's degree and doctorate in public administration from Virginia Tech. Dominion Energy is one of the nation's largest producers and transporters of energy, with a portfolio of approximately 26,200 megawatts of generation, 15,000 miles of natural gas transmission, gathering and storage pipeline, and 6,600 miles of electric transmission lines. Dominion operates one of the nation's largest natural gas storage systems with 1 trillion cubic feet of storage capacity and serves more than 6 million utility and retail energy customers. For more information, visit www.dom.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dominion-energy-promotes-blue-leopold-reid-to-executive-vice-president-300455549.html


News Article | May 22, 2017
Site: www.eurekalert.org

Much of what we thought we knew about the human papilloma virus (HPV) in HPV-related head and neck cancers may be wrong, according to a newly published study by Virginia Commonwealth University (VCU) researchers that analyzed data from The Human Cancer Genome Atlas. Head and neck cancers involving HPV are on the rise, and many experts believe we are seeing the start of an epidemic that will only get worse in the coming years. The Cancer Genome Atlas is a collaboration between the National Cancer Institute (NCI) and the National Human Genome Research (NHGR) Institute that makes publicly available genomic information on tumor samples from 33 different types of cancers. Its aim is to help the cancer research community improve the prevention, diagnosis and treatment of cancer. It is thought that there are two main forms of HPV-related cancers, episomal and integrated. In episomal variants, the HPV genome replicates independently. Integrated HPV has become part of the DNA of the host cell and relies on it for replication. Previously, it was believed that most HPV-related head and neck cancers had integrated HPV, as is what is believed with HPV-related cervical cancers. However, Windle's study, recently published in the journal Oncotarget, found that HPV DNA is maintained separate from the human genome in the majority of HPV-related head and neck cancers, though, in many cases, the HPV genome can acquire a small piece of human DNA making it look like integrated HPV. This viral-human hybrid represents a new category of episomal HPV in HPV-related cancers. "Our work challenges the idea that finding HPV DNA joined to human DNA means that HPV is integrated. With this new view of the state of HPV, we conclude that episomal HPV is the predominant state in HPV-related head and neck cancers," says Brad Windle, member of the Cancer Molecular Genetics research program at VCU Massey Cancer Center, professor at the Philips Institute for Oral Health Research at the VCU School of Dentistry and co-principle investigator on the study. "This is an important distinction because patients with episomal HPV cancer respond better to therapy than patients with integrated HPV cancer." Windle's team analyzed the genomes of all 520 HNC samples in The Cancer Genome Atlas and found that 72 were HPV positive. The large majority of these cancers had a common type of the virus known as HPV16 present, so they focused on that virus type. The data showed that 75 percent of the HPV16 samples had the HPV genome in the episomal state, and about half of the genomes contained a piece of human DNA within their circular structure. The researchers also found that 73 percent of the tumor samples were still dependent on proteins known as E1 and E2 for replication. This is important because when the HPV genome integrates with human DNA, expression of the HPV E2 protein--essential for independent replication--is lost. The presence of E2, or lack thereof, in tumor biopsies could be a reliable way for physicians to determine the cancer type and provide a more accurate prognosis. "Perhaps our most striking outcome is the potential to target the E1 and E2 proteins for diagnosis and treatment," says Windle. With nearly three quarters of these cancers dependent on E1 and E2 for replication, we could develop drugs that target these proteins and promote cell death." Windle's team plans to continue studying the integration of HPV in HPV-related head and neck cancers, and suggests that viral-human DNA hybrid HPV should be further explored in HPV-related cervical cancers. His team is currently working with Massey clinicians in order to use this information to assess patients' prognosis in the clinic. Windle collaborated on this research with Iain M. Morgan, director and professor at the Philips Institute for Oral Health Research at the VCU School of Dentistry, member of the Cancer Molecular Genetics research program at Massey and co-principle investigator on this study; Tara J. Nulton, from the Philips Institute for Oral Health Research at the VCU School of Dentistry; Amy L. Olex, from the C. Kenneth and Dianne Wright Center for Clinical and Translational Research at VCU; and Mikhail Dozmorov, Ph.D., from the C. Kenneth and Dianne Wright Center for Clinical and Translational Research and the Department of Biostatistics at VCU. This study was supported by a grant from the National Institute of Dental and Craniofacial Research, VCU's National Institutes of Health Clinical and Translational Science Awards (CTSA) grant UL1TR000058, and, in part, by VCU Massey Cancer Center's NCI Cancer Center Support Grant P30CA016059.


News Article | May 24, 2017
Site: www.prnewswire.com

Utilizing TriNetX's cloud-based, health research platform, members can analyze patient populations with search criteria across multiple longitudinal data points, and TriNetX's advanced analytics modules provide intelligence on which criteria have the most impact as well as the rate at which new patients present. Each data point in the TriNetX network can be traced to healthcare organizations who have the ability to identify individual patients, allowing clinical researchers to develop virtual patient cohorts that can be found in real-world clinical trial settings. Patients can be discovered for industry-sponsored and investigator-initiated studies, as well as for collaboration with peer research institutions. Data in the TriNetX network is fully de-identified to the user. "To help support VCU's strategic initiatives around cohort discovery and advances in precision medicine, we needed a searchable and extensible local data structure that included oncology and genomic data," said Aro. "We now have the capability to do cohort discovery of complementary patient populations within the TriNetX network to obtain adequate representation across the demographic spectrum, elucidation of rare disease populations and other challenging cohorts such as those with extensive inclusion/exclusion criteria." Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 225 degree and certificate programs in the arts, sciences and humanities. Seventy-nine of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. VCU Health represents the VCU Health System, which comprises five health sciences schools (Allied Health Professions, Dentistry, Medicine, Nursing, Pharmacy), VCU Medical Center (the only academic medical center and Level I trauma center in the region), Community Memorial Hospital, Children's Hospital of Richmond at VCU, VCU Massey Cancer Center and Virginia Premier. For more, please visit www.vcu.edu and vcuhealth.org. TriNetX is the global health research network enabling healthcare organizations, biopharma and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. Each member of our community shares in the consolidated value of our global, federated health research network that connects clinical researchers in real-time to the patient populations which they are attempting to study. For more information, visit http://www.trinetx.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/virginia-commonwealth-university-joins-the-trinetx-health-research-network-300463355.html


News Article | May 23, 2017
Site: www.businesswire.com

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Physicians at VCU Massey Cancer Center in Richmond, VA are the first in the world to successfully implant a new bio-absorbable, internal radiation treatment known as CivaSheet® to treat a patient with resectable pancreatic cancer. Approximately 53,000 patients per year in the US are diagnosed with pancreatic cancer, and of those, approximately 13,000 will undergo surgical resection. In March, a team of Massey cancer experts led by Emma Fields, M.D., radiation oncologist; Brian Kaplan M.D., surgical oncologist; and Dorin Todor, Ph.D., medical physicist, completed the procedure. A post-operative dosimetry study showed the radiation was effectively delivered, and no complications or radiation side effects have been reported. “There has never been another bio-absorbable, unidirectional radiation therapy implant with shielding like the CivaSheet,” Fields said. “Pancreatic cancer really is a perfect malignancy for use of this device, because the cancer is in a very difficult location to treat with radiation, the risk of residual cancer cells following surgery is high, and the disease is very aggressive.” Designed and manufactured by CivaTech Oncology, CivaSheet is a flexible, implantable intra-operative radiation therapy device (brachytherapy), which emits unidirectional radiation by integrating gold shielding. The unidirectional property makes the device active on one side only, and is entirely unique to CivaSheet. This allows physicians to safely deliver aggressive radiation doses immediately adjacent to healthy, sensitive tissue. Radiation is delivered as the isotope naturally decays over the course of several weeks – no repeated hospital trips are needed for radiation treatments. No follow-up procedure is necessary to remove the device. The implementation of CivaSheet occurs during a pancreatic cancer resection. In a short 15-minute operating room procedure, the surgical team cuts the CivaSheet to fit and affixes it to the area they want to treat. CivaSheet delivers a highly-targeted radiation dose to the immediate area where residual cancer cells potentially remain. Massey physicians expect CivaSheet to minimize side effects and improve local control of pancreatic cancer. “It’s a win-win,” Fields said. “The CivaSheet does not alter how long a patient waits for surgery, or complicate the surgeon’s responsibilities during the procedure.” The pancreas is located directly below the liver and behind the stomach. A portion of the small intestine, which is extremely sensitive to radiation, wraps around the head of the pancreas. “The beauty of the unidirectional CivaSheet is you can place it face-down on the tissue that the tumor was resected from - where the intestines will lay. Because of the built-in device shielding, the intestines are essentially protected from the radiation. With external beam radiation, it’s more difficult to pinpoint the tumor’s exact location, and protect the intestines to this degree,” Fields said. Current treatment protocols typically include a combination of chemotherapy and external beam radiation in the neoadjuvant (pre-operative) setting to shrink the tumor prior to surgery. The new approach with CivaSheet adds a strong “boost” of radiation to this technique, offering patients an opportunity for targeted, localized treatment. CivaSheet has broad FDA clearance to include pancreatic cancer and many other malignancies. A multi-center, NIH sponsored research protocol aimed at testing the device’s safety and efficacy on controlling pancreatic cancer is awaiting approval at Massey and several other nationally recognized cancer centers in the U.S. Additional press includes a full-length article on the CivaSheet, and a radio news segment from WCVE, an NPR news station. CivaTech Oncology Inc.® develops innovative products designed to deliver significant radiation doses in a manner that is safe and convenient for cancer patients. For more information, please visit www.civatechoncology.com.


Lille (France), Cambridge (Massachusetts, Etats-Unis), le 5 mai 2017 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique engagée dans la découverte et le développement de solutions thérapeutiques et diagnostiques dans le domaine des maladies métaboliques et inflammatoires touchant notamment la sphère hépato-gastroentérologique, a annoncé aujourd'hui l'inclusion du premier patient dans un essai de Phase 2a évaluant elafibranor dans la CBP. Dr. Velimir A. Luketic, MD, Département de Gastroentérologie, Hépatologie et Nutrition de l'Université Virginia Commonwealth (VCU), Richmond (Virginie, Etats-Unis) a commenté : « La PBC est une maladie chronique progressive du foie, caractérisée par la destruction par voie immunologique des petits canaux biliaires intra-hépatiques, et qui - si elle n'est pas traitée - progresse vers un stade terminal de maladie du foie ou d'insuffisance hépatique. Un nombre substantiel de patients ne profite pas des thérapies disponibles actuellement - UDCA ou OCA - soit à cause d'une absence de réponse soit à cause d'effets secondaires intolérables. Cela représente un besoin non satisfait majeur pour cette population. La littérature nous enseigne que le ciblage des récepteurs PPAR permet de réduire la synthèse des acides biliaires et de favoriser la détoxification de la bile dans les canaux biliaires. Dans les essais cliniques, les molécules ciblant les PPARs ont montré leur capacité à baisser l'ALP de manière significative et à améliorer le profil biochimique et le prurit chez les patients atteints de CBP. » Sophie Mégnien, Directeur Médical de GENFIT, a ajouté : « Nous sommes enthousiastes à l'idée de voir ce premier patient CBP randomisé dans cet essai de phase 2, et d'avancer avec notre programme CBP. Elafibranor, un double agoniste PPAR alpha & delta, est un candidat intéressant pour la CBP du fait de son impact sur la réduction des niveaux d'alkaline phosphatase, démontré dans des essais précédents, sur d'autres populations. Cet élément, avec ce que les PPARs ont par ailleurs systématiquement démontré en matière de réduction d'ALP, constitue un rationnel solide pour elafibranor dans la CBP. Démarrer la randomisation dans ce type de maladie, rare, est une étape importante, et nous espérons qu'elafibranor apportera un véritable bénéfice aux patients, pour finalement répondre au besoin encore non satisfait. » Elafibranor est le composé le plus avancé du portefeuille de GENFIT. Elafibranor est un traitement de type « first-in-class », Agoniste du Récepteur Activé par les Proliférateurs des Peroxysomes alpha et delta, administré une fois par jour par voie orale, et développé pour traiter notamment la stéatohépatite non-alcoolique (NASH). Elafibranor est considéré comme capable de traiter les multiples facettes de la NASH telles que l'inflammation, la sensibilité à l'insuline, les profils lipidique et métabolique, les marqueurs du foie. GENFIT est une société biopharmaceutique dédiée à la découverte et au développement de médicaments dans des domaines thérapeutiques où les besoins médicaux sont considérables en raison du manque de traitements efficaces et du fait de l'augmentation du nombre de malades au niveau mondial. GENFIT concentre ses efforts de R&D pour participer à la mise sur le marché de solutions thérapeutiques visant à combattre certaines maladies métaboliques, inflammatoires, autoimmunes ou fibrotiques touchant en particulier le foie (comme la stéatohépatite non alcoolique ou NASH) et plus généralement la sphère gastro-intestinale. GENFIT déploie des approches combinant nouveaux traitements et biomarqueurs. Elafibranor, composé propriétaire de GENFIT le plus avancé, est en cours de phase 3 d'essais cliniques. Installée à Lille, Paris et Cambridge, MA (USA), l'entreprise compte environ 130 collaborateurs. GENFIT est une société cotée sur le marché réglementé d'Euronext à Paris, Compartiment B (Euronext : GNFT - ISIN : FR0004163111). www.genfit.fr Avertissement Ce communiqué de presse contient des déclarations prospectives. Bien que la Société considère que ses projections sont basées sur des hypothèses raisonnables, ces déclarations prospectives peuvent être remises en cause par un certain nombre d'aléas et d'incertitudes, ce qui pourrait donner lieu à des résultats substantiellement différents de ceux décrits, induits ou anticipés dans lesdites déclarations prospectives. Ces aléas et incertitudes comprennent notamment les incertitudes inhérentes à la recherche et développement, y compris dans le domaine des biomarqueurs, au progrès et aux résultats de l'essai clinique RESOLVE-IT, aux examens et autorisations d'autorités réglementaires comme la FDA et l'EMA concernant notamment Elafibranor dans la NASH, la CBP et d'autres indications, ainsi que les biomarqueurs développés par la Société, au succès d'une stratégie d'in-licensing, à la capacité de la Société à continuer à lever des fonds pour son développement, ainsi qu'à ceux développés à la section 4 «Principaux Risques et incertitudes» du Document de Référence enregistré par l'Autorité des marchés financiers (AMF) le 28 avril 2017 sous le numéro R.17-034 disponible sur les sites Internet de GENFIT (www.genfit.fr) et de l'AMF (www.amf-france.org). Sous réserve de la réglementation applicable, la Société ne prend aucun engagement de mise à jour ou de révision des informations contenues dans ce communiqué.


Lille (France), Cambridge (Massachusetts, Etats-Unis), le 5 mai 2017 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique engagée dans la découverte et le développement de solutions thérapeutiques et diagnostiques dans le domaine des maladies métaboliques et inflammatoires touchant notamment la sphère hépato-gastroentérologique, a annoncé aujourd'hui l'inclusion du premier patient dans un essai de Phase 2a évaluant elafibranor dans la CBP. Dr. Velimir A. Luketic, MD, Département de Gastroentérologie, Hépatologie et Nutrition de l'Université Virginia Commonwealth (VCU), Richmond (Virginie, Etats-Unis) a commenté : « La PBC est une maladie chronique progressive du foie, caractérisée par la destruction par voie immunologique des petits canaux biliaires intra-hépatiques, et qui - si elle n'est pas traitée - progresse vers un stade terminal de maladie du foie ou d'insuffisance hépatique. Un nombre substantiel de patients ne profite pas des thérapies disponibles actuellement - UDCA ou OCA - soit à cause d'une absence de réponse soit à cause d'effets secondaires intolérables. Cela représente un besoin non satisfait majeur pour cette population. La littérature nous enseigne que le ciblage des récepteurs PPAR permet de réduire la synthèse des acides biliaires et de favoriser la détoxification de la bile dans les canaux biliaires. Dans les essais cliniques, les molécules ciblant les PPARs ont montré leur capacité à baisser l'ALP de manière significative et à améliorer le profil biochimique et le prurit chez les patients atteints de CBP. » Sophie Mégnien, Directeur Médical de GENFIT, a ajouté : « Nous sommes enthousiastes à l'idée de voir ce premier patient CBP randomisé dans cet essai de phase 2, et d'avancer avec notre programme CBP. Elafibranor, un double agoniste PPAR alpha & delta, est un candidat intéressant pour la CBP du fait de son impact sur la réduction des niveaux d'alkaline phosphatase, démontré dans des essais précédents, sur d'autres populations. Cet élément, avec ce que les PPARs ont par ailleurs systématiquement démontré en matière de réduction d'ALP, constitue un rationnel solide pour elafibranor dans la CBP. Démarrer la randomisation dans ce type de maladie, rare, est une étape importante, et nous espérons qu'elafibranor apportera un véritable bénéfice aux patients, pour finalement répondre au besoin encore non satisfait. » Elafibranor est le composé le plus avancé du portefeuille de GENFIT. Elafibranor est un traitement de type « first-in-class », Agoniste du Récepteur Activé par les Proliférateurs des Peroxysomes alpha et delta, administré une fois par jour par voie orale, et développé pour traiter notamment la stéatohépatite non-alcoolique (NASH). Elafibranor est considéré comme capable de traiter les multiples facettes de la NASH telles que l'inflammation, la sensibilité à l'insuline, les profils lipidique et métabolique, les marqueurs du foie. GENFIT est une société biopharmaceutique dédiée à la découverte et au développement de médicaments dans des domaines thérapeutiques où les besoins médicaux sont considérables en raison du manque de traitements efficaces et du fait de l'augmentation du nombre de malades au niveau mondial. GENFIT concentre ses efforts de R&D pour participer à la mise sur le marché de solutions thérapeutiques visant à combattre certaines maladies métaboliques, inflammatoires, autoimmunes ou fibrotiques touchant en particulier le foie (comme la stéatohépatite non alcoolique ou NASH) et plus généralement la sphère gastro-intestinale. GENFIT déploie des approches combinant nouveaux traitements et biomarqueurs. Elafibranor, composé propriétaire de GENFIT le plus avancé, est en cours de phase 3 d'essais cliniques. Installée à Lille, Paris et Cambridge, MA (USA), l'entreprise compte environ 130 collaborateurs. GENFIT est une société cotée sur le marché réglementé d'Euronext à Paris, Compartiment B (Euronext : GNFT - ISIN : FR0004163111). www.genfit.fr Avertissement Ce communiqué de presse contient des déclarations prospectives. Bien que la Société considère que ses projections sont basées sur des hypothèses raisonnables, ces déclarations prospectives peuvent être remises en cause par un certain nombre d'aléas et d'incertitudes, ce qui pourrait donner lieu à des résultats substantiellement différents de ceux décrits, induits ou anticipés dans lesdites déclarations prospectives. Ces aléas et incertitudes comprennent notamment les incertitudes inhérentes à la recherche et développement, y compris dans le domaine des biomarqueurs, au progrès et aux résultats de l'essai clinique RESOLVE-IT, aux examens et autorisations d'autorités réglementaires comme la FDA et l'EMA concernant notamment Elafibranor dans la NASH, la CBP et d'autres indications, ainsi que les biomarqueurs développés par la Société, au succès d'une stratégie d'in-licensing, à la capacité de la Société à continuer à lever des fonds pour son développement, ainsi qu'à ceux développés à la section 4 «Principaux Risques et incertitudes» du Document de Référence enregistré par l'Autorité des marchés financiers (AMF) le 28 avril 2017 sous le numéro R.17-034 disponible sur les sites Internet de GENFIT (www.genfit.fr) et de l'AMF (www.amf-france.org). Sous réserve de la réglementation applicable, la Société ne prend aucun engagement de mise à jour ou de révision des informations contenues dans ce communiqué.


Lille (France), Cambridge (Massachusetts, Etats-Unis), le 5 mai 2017 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique engagée dans la découverte et le développement de solutions thérapeutiques et diagnostiques dans le domaine des maladies métaboliques et inflammatoires touchant notamment la sphère hépato-gastroentérologique, a annoncé aujourd'hui l'inclusion du premier patient dans un essai de Phase 2a évaluant elafibranor dans la CBP. Dr. Velimir A. Luketic, MD, Département de Gastroentérologie, Hépatologie et Nutrition de l'Université Virginia Commonwealth (VCU), Richmond (Virginie, Etats-Unis) a commenté : « La PBC est une maladie chronique progressive du foie, caractérisée par la destruction par voie immunologique des petits canaux biliaires intra-hépatiques, et qui - si elle n'est pas traitée - progresse vers un stade terminal de maladie du foie ou d'insuffisance hépatique. Un nombre substantiel de patients ne profite pas des thérapies disponibles actuellement - UDCA ou OCA - soit à cause d'une absence de réponse soit à cause d'effets secondaires intolérables. Cela représente un besoin non satisfait majeur pour cette population. La littérature nous enseigne que le ciblage des récepteurs PPAR permet de réduire la synthèse des acides biliaires et de favoriser la détoxification de la bile dans les canaux biliaires. Dans les essais cliniques, les molécules ciblant les PPARs ont montré leur capacité à baisser l'ALP de manière significative et à améliorer le profil biochimique et le prurit chez les patients atteints de CBP. » Sophie Mégnien, Directeur Médical de GENFIT, a ajouté : « Nous sommes enthousiastes à l'idée de voir ce premier patient CBP randomisé dans cet essai de phase 2, et d'avancer avec notre programme CBP. Elafibranor, un double agoniste PPAR alpha & delta, est un candidat intéressant pour la CBP du fait de son impact sur la réduction des niveaux d'alkaline phosphatase, démontré dans des essais précédents, sur d'autres populations. Cet élément, avec ce que les PPARs ont par ailleurs systématiquement démontré en matière de réduction d'ALP, constitue un rationnel solide pour elafibranor dans la CBP. Démarrer la randomisation dans ce type de maladie, rare, est une étape importante, et nous espérons qu'elafibranor apportera un véritable bénéfice aux patients, pour finalement répondre au besoin encore non satisfait. » Elafibranor est le composé le plus avancé du portefeuille de GENFIT. Elafibranor est un traitement de type « first-in-class », Agoniste du Récepteur Activé par les Proliférateurs des Peroxysomes alpha et delta, administré une fois par jour par voie orale, et développé pour traiter notamment la stéatohépatite non-alcoolique (NASH). Elafibranor est considéré comme capable de traiter les multiples facettes de la NASH telles que l'inflammation, la sensibilité à l'insuline, les profils lipidique et métabolique, les marqueurs du foie. GENFIT est une société biopharmaceutique dédiée à la découverte et au développement de médicaments dans des domaines thérapeutiques où les besoins médicaux sont considérables en raison du manque de traitements efficaces et du fait de l'augmentation du nombre de malades au niveau mondial. GENFIT concentre ses efforts de R&D pour participer à la mise sur le marché de solutions thérapeutiques visant à combattre certaines maladies métaboliques, inflammatoires, autoimmunes ou fibrotiques touchant en particulier le foie (comme la stéatohépatite non alcoolique ou NASH) et plus généralement la sphère gastro-intestinale. GENFIT déploie des approches combinant nouveaux traitements et biomarqueurs. Elafibranor, composé propriétaire de GENFIT le plus avancé, est en cours de phase 3 d'essais cliniques. Installée à Lille, Paris et Cambridge, MA (USA), l'entreprise compte environ 130 collaborateurs. GENFIT est une société cotée sur le marché réglementé d'Euronext à Paris, Compartiment B (Euronext : GNFT - ISIN : FR0004163111). www.genfit.fr Avertissement Ce communiqué de presse contient des déclarations prospectives. Bien que la Société considère que ses projections sont basées sur des hypothèses raisonnables, ces déclarations prospectives peuvent être remises en cause par un certain nombre d'aléas et d'incertitudes, ce qui pourrait donner lieu à des résultats substantiellement différents de ceux décrits, induits ou anticipés dans lesdites déclarations prospectives. Ces aléas et incertitudes comprennent notamment les incertitudes inhérentes à la recherche et développement, y compris dans le domaine des biomarqueurs, au progrès et aux résultats de l'essai clinique RESOLVE-IT, aux examens et autorisations d'autorités réglementaires comme la FDA et l'EMA concernant notamment Elafibranor dans la NASH, la CBP et d'autres indications, ainsi que les biomarqueurs développés par la Société, au succès d'une stratégie d'in-licensing, à la capacité de la Société à continuer à lever des fonds pour son développement, ainsi qu'à ceux développés à la section 4 «Principaux Risques et incertitudes» du Document de Référence enregistré par l'Autorité des marchés financiers (AMF) le 28 avril 2017 sous le numéro R.17-034 disponible sur les sites Internet de GENFIT (www.genfit.fr) et de l'AMF (www.amf-france.org). Sous réserve de la réglementation applicable, la Société ne prend aucun engagement de mise à jour ou de révision des informations contenues dans ce communiqué.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "China New Energy Vehicle Power Electronics Industry Report, 2017-2020" report to their offering. New energy vehicle electronic technology generally consists of battery management system (BMS), on-board charger, inverter, vehicle control unit (VCU)/hybrid control unit (HCU), pedestrian detection system, DC/DC, etc.. BMS, motor control inverter and VCU/HCU as core components of new energy vehicle must have very high security and reliability. New energy vehicle power electronics usually include AC/DC charger, DC-AC inverter and DC-DC; besides, there are motor controller for electric A/C compressor, PTC heater for electric A/C and others. In the future, DC/DC converter and inverter will be integrated into new energy vehicle power controller, similar to VCU integration effect. However, the controller is generally placed in the nearest inverter unit to make software system shape a larger integration. For more information about this report visit http://www.researchandmarkets.com/research/bv3wmr/china_new_energy


News Article | February 15, 2017
Site: www.prweb.com

AVIE! MedSpa and Laser Center is excited to introduce the “Before and After” Visualizer for Ultherapy®, a non-invasive treatment that uses ultrasound energy to tighten and lift loose, sagging skin on the face, neck, jawline, chin, brow, and chest. This exciting new visualization technology affords patients a “sneak peak” of their Ultherapy results before they undergo the treatment. Using an actual photograph of the patient, this new technology creates a realistic depiction of a person’s unique results by providing a digitally-generated “after” image of their Ultherapy treatment. A non-surgical alternative to a facelift, FDA-cleared Ultherapy uses ultrasound imaging to target and deliver ultrasound energy directly to problem areas. Ultherapy can tighten from deep within the skin’s foundation and promote new collagen growth for added elasticity, leaving skin looking younger and firmer. The winner of PoshSEVEN’s Best of Suburbia Beauty Award in 2016, AVIE! MedSpa and Laser Center is an Ultherapy Ultra Treatment Provider, which acknowledges AVIE! for providing a high number of Ultherapy treatments with exceptional outcomes. About AVIE! MedSpa & Laser Center AVIE! MedSpa & Laser Center has been offering the latest in cosmetic medical spa treatments in a relaxing spa environment in Leesburg, VA since opening in March 2009. MedSpa Owner and Master Aesthetician, Kim Marinetto, RN, in conjunction with Medical Director Khalique Zahir, MD and their highly skilled team of nurses, nurse practitioners and aestheticians, provide specialized cosmetic and aesthetic programs so each of their clients’ needs are addressed on an individual basis with personalized follow-ups. Aesthetic treatments at AVIE! have minimal to no downtime. Services include: CoolSculpting®, Vela® Shape III, Ultherapy®, Botox®, Juvéderm®, Juvéderm® Ultra Plux XC, Restylane®, Restylane® Silk, Restylane Lyft®, Voluma™ XC, Volbella®, Chemical Peels, MicroLaserPeels, Photo Facials, HydraFacial, Dermaplaning, Skin Tightening, Pro Fractional Skin Resurfacing, Laser Hair Removal, Professional Skin Analysis, PRP, Vitamin B12 shots, HD Brows, and Blepharoplasty by Dr. Zahir. With over 20 years of experience administering injectables, AVIE! has performed over 100,000 Botox and dermal filler treatments since 2009. AVIE! also carries physician level skin care and makeup. Consultations are complimentary, and financing is available. For more information please call 703-737-0197 or visit http://www.aviemedspa.com. About Kim Marinetto, RN & Master Aesthetician Kim Marinetto has over 20 years of experience as a Registered Nurse, and in the past seven years has focused her practice on cosmetic medicine, adding to her credentials a Medical Aesthetician Certification in 2006, along with additional certifications in Botox Cosmetic, Facial Fillers, Sclerotherapy, and various advanced laser systems. Kim is a Master Aesthetician in the state of Virginia. Additionally, Kim has done extensive training on laser technology and her coursework is recognized by the AMA. About Khalique Zahir, MD Dr. Khalique Zahir, Medical Director of AVIE! Medspa and Laser Center, graduated from West Virginia School of Medicine and is board-certified by the American Board of Plastic Surgery and The American Board of Surgery. Dr. Zahir practiced general surgery from 1992 – 1999 at West Virginia University and St. Mary’s Hospital, then cosmetic, plastic, and reconstructive surgery at Vanderbilt University Medical Center from 1999 – 2001. Dr. Zahir also holds a Virginia Medical License and a Maryland Medical License. He has written over 20 articles published in national health journals and is an Assistant Clinical Professor of Surgery at VCU School of Medicine.


News Article | February 15, 2017
Site: www.prweb.com

Tribble Insurance Agency, a family owned and operated firm offering asset protection and financial planning services to the eastern Virginia region, is inaugurating a charity event to honor Chad Phillip Dermyer, a local police trooper who was shot and killed serving his community. While on duty last year, Chad Phillip Dermyer and his fellow officers were conducting routine stops of suspects when one of them, a violent career criminal, suddenly produced a handgun and opened fire. Officer Dermyer was critically wounded and rushed to the VCU Medical Center where he succumbed to his injuries. Trooper Dermyer was 37 years old and is survived by his wife and two young children. “Make no mistake, trooper Dermyer was a hero who gave his life in the highest form of service, and this charity event will help support his family while honoring his memory,” says Trip Tribble, owner and executive manager of the Tribble Insurance Agency. To broadcast updates on the charity event and gather support from local communities, Tribble and his team are making connections with readers over social media platforms and an email bulletin system. Further efforts to generate publicity for the event will include a feature story scheduled for publication in “Our Hometown,” a monthly online periodical produced by Tribble Insurance: http://tribbleinsuranceagency.com/Our-Hometown-Magazine_39. The charity event honoring officer Dermyer marks the 10th charitable cause supported by the Tribble Agency over the last year and a half. As members of the national charity support network “Agents of Change,” Tribble and his team are committed to hosting additional charity events for nonprofits in the eastern Virginia region on a bimonthly basis. All those who wish to know more about the charity event honoring fallen officer Dermyer, and those who wish to take action and be part of the event, are invited by the Tribble Insurance team to visit the following page: http://tribbleinsuranceagency.com/Honoring-a-Fallen-Hero_30_community_cause. Readers interested in learning more about other charitable endeavors undertaken by the Tribble Insurance Agency can bookmark the firm’s list of Community Causes here: http://tribbleinsuranceagency.com/community-cause?page=1. As a Personal Finance Representative in Ashland, agency owner Trip Tribble knows many local families. His knowledge and understanding of the people in his community ensures that clients of Tribble Insurance Agency are provided with an outstanding level of service. Trip and his team look forward to helping families protect the things that are most important - family, home, car and more. Tribble Insurance Agency also offers clients a preparation strategy for achieving their financial goals. To contact an expert at Tribble Insurance Agency, visit http://tribbleinsuranceagency.com/ or call (804) 550-0900.

Loading VCU collaborators
Loading VCU collaborators